Filtered By:
Condition: Bleeding
Countries: USA Health
This page shows you your search results in order of relevance. This is page number 7.
Order by Relevance | Date
Total 173 results found since Jan 2013.
Protamine Reduces the Risk of Serious Bleeding at the Time of CEA without Increased Risk of Stroke, MI or Death
Introduction: Controversy persists regarding the use of Protamine during carotid endarterectomy (CEA) despite real world evidence to support its use. The purpose of this study was to best determine the impact of protamine reversal of heparin anticoagulation on the outcome of CEA throughout the United States.
Source: European Journal of Vascular and Endovascular Surgery - November 30, 2019 Category: Surgery Authors: David Stone, Kristina Giles, Bjoern Suckow, Philip Goodney, Thomas Huber, Richard Powell, Jack Cronenwett, Salvatore Scali Source Type: research
Readmissions after Acute Kidney Injury during Left Ventricular Assist Device Implantation Hospitalization.
CONCLUSION: AKI-D was associated with highest -30-day readmission risk, possibly related to negatively synergistic effects of LVAD, kidney dysfunction, and dialysis related factors on infection and GI bleeding risks. AKI alone was not associated with increased readmission risk.
PMID: 31962311 [PubMed - as supplied by publisher]
Source: American Journal of Nephrology - January 20, 2020 Category: Urology & Nephrology Authors: Walther CP, Winkelmayer WC, Deswal A, Niu J, Navaneethan SD Tags: Am J Nephrol Source Type: research
Status, Indications, and Use of Cardiac Replacement Therapy in the Era of Multimodal Mechanical Approaches to Circulatory Support: A Scoping Review
In conclusion, the Syncardia temporary TAH is a reasonable bridge-to-transplant option for selected patients with either biventricular failure or special anatomic conditions.RésuméLes auteurs décrivent l’utilisation, les indications et les résultats actuels du cœur artificiel total (CAT) temporaire Syncardia (Syncardia Systems, Tucson, AZ, États-Unis), le seul CAT actuellement approuvé comme stratégie de transition vers une transplantation au Canada, aux États-Unis et en Europe. Implanté chez plus de 1 700 patients dans le monde, le CAT temporaire Syncardia est la pompe la plus utilisée. À l’échelle mondia...
Source: Canadian Journal of Cardiology - February 7, 2020 Category: Cardiology Source Type: research
Outcomes of Percutaneous Coronary Intervention in Cardiac Transplant Patients: A Binational Analysis Derived From the United Kingdom and United States.
CONCLUSIONS: PCI in cardiac transplant recipients was associated with similar short-term mortality and vascular complications compared with PCI in the general populace. However, a higher 1-year morality was observed in the BCIS cohort.
PMID: 32865507 [PubMed - in process]
Source: The Journal of Invasive Cardiology - September 2, 2020 Category: Cardiology Tags: J Invasive Cardiol Source Type: research
Common Antidepressants Won ' t Raise Risk for Bleeding Strokes: Study
FRIDAY, Feb. 26, 2021 -- The most widely prescribed antidepressants in the United States don ' t appear to increase the risk of the deadliest type of stroke, according to a new preliminary study.
It examined the association between selective...
Source: Drugs.com - Daily MedNews - February 26, 2021 Category: General Medicine Source Type: news
Cardioversion of Atrial Fibrillation with Acupuncture
Conclusions: Acupuncture appears to be solely responsible for the conversion of atrial fibrillation to sinus rhythm in this case, as no β-blockers, calcium channel blockers, or antiarrhythmic medicines were administered before the return to sinus rhythm. The antiarrhythmic effect noted may be from centrally mediated autonomic effects or additional mechanisms. Further study will help to define the role of acupuncture in the management of acute arrhythmias.PMID:34239665 | PMC:PMC8236297 | DOI:10.1089/acu.2021.0022
Source: Acupuncture in Medicine - July 9, 2021 Category: Complementary Medicine Authors: Stephen Olex Source Type: research
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
